# US 2022/0033780 A1 · Method for preparing intestinal organoid derived from pluripotent stem cell

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033780 A1
- Document ID: US20220033780A1
- Status: Published application
- Kind: A1
- Application number: 17/290,446
- Filed: 2019-10-31
- Published: 2022-02-03
- Earliest claimed: 2018-11-02
- Assignees: Public University Corporation Nagoya City University
- Applicants: Public University Corporation Nagoya City University
- Inventors: Tamihide MATSUNAGA; Takahiro IWAO; Daichi ONOZATO; Isamu OGAWA
- Web page: https://patentgrep.com/patent/US20220033780A1

## CPC

- C12N 5/0679: {Cells of the gastro-intestinal tract}
- G01N 33/5082: {Supracellular entities, e.g. tissue, organisms}
- A61L 27/3804: {characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells}
- G01N 33/5014: {for testing toxicity}
- G01N 33/5044: {involving specific cell types}
- C12N 2500/32: Amino acids
- C12N 2501/01: Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
- C12N 2501/11: Epidermal growth factor [EGF]
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/119: Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2501/16: Activin; Inhibin; Mullerian inhibiting substance
- C12N 2501/415: Wnt; Frizzeled
- C12N 2501/72: Transferases [EC 2.]
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2501/734: Proteases (EC 3.4.)
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2533/52: Fibronectin; Laminin
- C12N 2533/70: Polysaccharides
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

An object is to prepare an intestinal organoid having a characteristic close to the small intestine of a living body, from a pluripotent stem cell. An intestinal organoid is prepared from a pluripotent stem cell, by the following steps of: (1) differentiating the pluripotent stem cell into an endoderm-like cell; (2) differentiating the endoderm-like cell obtained in step (1) into an intestinal stem cell-like cell; (3) culturing the intestinal stem cell-like cell obtained in step (2) in the presence of an epidermal growth factor, a fibroblast growth factor, a TGF β receptor inhibitor, a GSK-3 β inhibitor, and a ROCK inhibitor; (4) culturing the cell obtained in step (3) to form a spheroid; and (5) differentiating the spheroid formed in step (4) to form an intestinal organoid, wherein the differentiation includes culturing in the presence of an epidermal growth factor, a BMP inhibitor, and a Wnt signal activator. Also, a plane culture system is prepared by subjecting the cells constituting the intestinal organoid formed in step (5) to plane culture in the presence of an epidermal growth factor and a TGF β receptor inhibitor. A highly functional evaluation system having the villi structure is constructed by using air-liquid interface culture in the plane culture.

## Claims

### Claim 1

A method for preparation of an intestinal organoid from a pluripotent stem cell, comprising the following steps (1) to (5):
(1) differentiating the pluripotent stem cell into an endoderm-like cell;
(2) differentiating the endoderm-like cell obtained in step (1) into an intestinal stem cell-like cell;
(3) culturing the intestinal stem cell-like cell obtained in step (2) in the presence of an epidermal growth factor, a fibroblast growth factor, a TGF β receptor inhibitor, a GSK-3 β inhibitor, and a ROCK inhibitor;
(4) culturing the cell obtained in step (3) to form a spheroid; and
(5) differentiating the spheroid formed in step (4) to form an intestinal organoid, wherein the differentiation comprises culturing in the presence of an epidermal growth factor, a BMP inhibitor, and a Wnt signal activator.

### Claim 2 (depends on 1)

The preparation method according to claim 1, wherein the culture of step (3) is carried out by using a culture surface coated with a basal membrane component.

### Claim 3 (depends on 2)

The preparation method according to claim 2, wherein the basal membrane component is laminin 511 or an E8 fragment thereof.

### Claim 4 (depends on 1)

The preparation method according to claim 1, wherein, in step (3), a procedure for passage culture is carried out.

### Claim 5 (depends on 4)

The preparation method according to claim 4, wherein the number of times of the procedure for passage culture is 1 or 2.

### Claim 6 (depends on 1)

The preparation method according to claim 1, wherein the fibroblast growth factor is FGF2, FGF4 or FGF10; the TGF β receptor inhibitor is A-83-01; the GSK-3 β inhibitor is CHIR99021, SB216763, CHIR98014, TWS119, Tideglusib, SB415286, BIO, AZD2858, AZD1080, AR-A014418, TDZD-8, LY2090314, IM-12, Indirubin, Bikinin or 1-Azakenpaullone; and the ROCK inhibitor is Y-27632.

### Claim 7 (depends on 1)

The preparation method according to claim 1, wherein the period of the culture of step (3) is 2 to 14 days.

### Claim 8 (depends on 1)

The preparation method according to claim 1, wherein, in the culture of step (4), a plurality of spheroids are simultaneously formed by using a culture vessel having a plurality of wells uniform in shape and size formed on a low cell-adhesive or non cell-adhesive culture surface.

### Claim 9 (depends on 1)

The preparation method according to claim 1, wherein a plurality of spheroids formed in step (4) are simultaneously cultured in a suspension state, by using a liquid medium adding a material for forming a three-dimensional network structure in an aqueous solution for the culture of step (5).

### Claim 10 (depends on 9)

The preparation method according to claim 9, wherein the material is at least one selected from the group consisting of a polymer gel and a polysaccharide.

### Claim 11 (depends on 9)

The preparation method according to claim 9, wherein the material comprises deacylated gellan gum.

### Claim 12 (depends on 1)

The preparation method according to claim 1, wherein, the BMP inhibitor is Noggin, and the Wnt signal activator is R-spondin-1.

### Claim 13 (depends on 1)

The preparation method according to claim 1, wherein the culture period of step (5) is 12 to 36 days.

### Claim 14 (depends on 1)

The preparation method according to claim 1, wherein the culture of step (5) is carried out in the presence of an MEK1/2 inhibitor, a DNA methylation inhibitor, a TGF β receptor inhibitor, and a y-secretase inhibitor in addition to an epidermal growth factor, a BMP inhibitor, and a Wnt signal activator.

### Claim 15 (depends on 1)

The preparation method according to claim 1, wherein the culture of step (5) is carried out in the presence of an MEK1/2 inhibitor, a DNA methylation inhibitor, and a TGF β receptor inhibitor in addition to an epidermal growth factor, a BMP inhibitor, and a Wnt signal activator.

### Claim 16 (depends on 1)

The preparation method according to claim 1, wherein the pluripotent stem cell is an induced pluripotent stem cell or an embryonic stem cell.

### Claim 17 (depends on 1)

The preparation method according to claim 1, wherein the pluripotent stem cell is a human induced pluripotent stem cell.

### Claim 18 (depends on 17)

The preparation method according to claim 17, wherein the human induced pluripotent stem cell is derived from a patient having an intestinal disease.

### Claim 19 (depends on 1)

An intestinal organoid obtained by the preparation method according to claim 1.

### Claim 20 (depends on 19)

A method for evaluating in vivo kinetics or toxicity of a test substance by using the intestinal organoid according to claim 19.

### Claim 21 (depends on 20)

The evaluation method according to claim 20, wherein the in vivo kinetics is metabolism, absorbency, membrane permeability, drug interaction, induction of a drug-metabolizing enzyme, or induction of a drug transporter.

### Claim 22 (depends on 19, 21)

The method according to claim 21, comprising the following steps (I) and (II):
(I) contacting the test substance with the intestinal organoid according to claim 19; and
(II) determining/evaluating test substance's metabolism, absorbency, membrane permeability, drug interaction, induction of a drug-metabolizing enzyme, or induction of a drug transporter, or toxicity.

### Claim 23 (depends on 1)

A method for preparing an intestinal disease model, comprising inducing a pathological condition of an intestinal disease in the intestinal organoid obtained by the preparation method according to claim 1.

### Claim 24 (depends on 19)

A transplant material comprising the intestinal organoid according to claim 19.

### Claim 25

A preparation method for an intestinal tract cell layer from a pluripotent stem cell, comprising the following steps (1) to (6):
(1) differentiating the pluripotent stem cell into an endoderm-like cell;
(2) differentiating the endoderm-like cell obtained in step (1) into an intestinal stem cell-like cell;
(3) culturing the intestinal stem cell-like cell obtained in step (2) in the presence of an epidermal growth factor, a fibroblast growth factor, a TGF β receptor inhibitor, a GSK-3 β inhibitor, and a ROCK inhibitor;
(4) culturing the cell obtained in step (3) to form a spheroid;
(5) differentiating the spheroid formed in step (4) to form an intestinal organoid, wherein the differentiation comprises culturing in the presence of an epidermal growth factor, a BMP inhibitor, and a Wnt signal activator; and
(6) subjecting the cells constituting the intestinal organoid formed in step (5) to plane culture carried out in the presence of an epidermal growth factor and a TGF β receptor inhibitor.

### Claim 26 (depends on 25)

The preparation method according to claim 25, wherein the culture of step (6) is carried out in the presence of a cAMP activation substance in addition to an epidermal growth factor and a TGF β receptor inhibitor.

### Claim 27 (depends on 25)

The preparation method according to claim 25, wherein the culture of step (6) is carried out in the presence of a cAMP activation substance and a y-secretase inhibitor in addition to an epidermal growth factor and a TGF β receptor inhibitor.

### Claim 28 (depends on 25)

The preparation method according to claim 25, wherein the culture of step (6) is carried out in the presence of a cAMP activation substance and a GSK-3 β inhibitor in addition to an epidermal growth factor and a TGF β receptor inhibitor.

### Claim 29 (depends on 25)

The preparation method according to claim 25, wherein at least part of the plane culture of step (6) is air-liquid interface culture.

### Claim 30 (depends on 29)

The preparation method according to claim 29, wherein the air-liquid interface culture is carried out in the presence of a factor activating a cAMP signal in addition to an epidermal growth factor and a TGF β receptor inhibitor.

### Claim 31 (depends on 30)

The preparation method according to claim 30, wherein the factor is a cAMP derivative, a cAMP-degrading enzyme inhibitor or a cAMP activation substance.

### Claim 32 (depends on 30)

The preparation method according to claim 30, wherein the factor is forskolin.

### Claim 33 (depends on 25)

An intestinal tract cell layer obtained by the method according to claim 25.

### Claim 34 (depends on 33)

A method for evaluating in vivo kinetics or toxicity of a test substance by using the intestinal tract cell layer according to claim 33.

### Claim 35 (depends on 34)

The method according to claim 34, wherein the in vivo kinetics is metabolism, absorbency, membrane permeability, drug interaction, induction of a drug-metabolizing enzyme, or induction of a drug transporter.

### Claim 36 (depends on 34)

The method according to claim 34, comprising the following steps (i) to (iii):
(i) preparing an intestinal tract cell layer by the method recited below;
(ii) contacting a test substance with the intestinal tract cell layer; and
(iii) quantifying the test substance passed through the intestinal tract cell layer and evaluating the test substance's metabolism, absorbency, membrane permeability, drug interaction, induction of a drug-metabolizing enzyme, or induction of a drug transporter, or toxicity,
wherein the method of preparing the intestinal tract cell layer is a method of preparing an intestinal tract cell layer from a pluripotent stem cell, comprising the following steps (1) to (6):
(1) differentiating the pluripotent stem cell into an endoderm-like cell;
(2) differentiating the endoderm-like cell obtained in step (1) into an intestinal stem cell-like cell;
(3) culturing the intestinal stem cell-like cell obtained in step (2) in the presence of an epidermal growth factor, a fibroblast growth factor, a TGF β receptor inhibitor, a GSK-3 β inhibitor, and a ROCK inhibitor;
(4) culturing the cell obtained in step (3) to form a spheroid;
(5) differentiating the spheroid formed in step (4) to form an intestinal organoid, wherein the differentiation comprises culturing in the presence of an epidermal growth factor, a BMP inhibitor, and a Wnt signal activator; and
(6) subjecting the cells constituting the intestinal organoid formed in step (5) to plane culture carried out in the presence of an epidermal growth factor and a TGF β receptor inhibitor.

### Claim 37 (depends on 34)

The method according to claim 34, comprising the following steps (I) and (II):
(I) contacting the test substance with an intestinal tract cell layer prepared by the method recited below; and
(II) determining/evaluating test substance's metabolism, absorbency, membrane permeability, drug interaction, induction of a drug-metabolizing enzyme, or induction of a drug transporter, or toxicity,
wherein the method of preparing the intestinal tract cell layer is a method of preparing an intestinal tract cell layer from a pluripotent stem cell, comprising the following steps (1) to (6):
(1) differentiating the pluripotent stem cell into an endoderm-like cell;
(2) differentiating the endoderm-like cell obtained in step (1) into an intestinal stem cell-like cell;
(3) culturing the intestinal stem cell-like cell obtained in step (2) in the presence of an epidermal growth factor, a fibroblast growth factor, a TGF β receptor inhibitor, a GSK-3 β inhibitor, and a ROCK inhibitor;
(4) culturing the cell obtained in step (3) to form a spheroid;
(5) differentiating the spheroid formed in step (4) to form an intestinal organoid, wherein the differentiation comprises culturing in the presence of an epidermal growth factor, a BMP inhibitor, and a Wnt signal activator; and
(6) subjecting the cells constituting the intestinal organoid formed in step (5) to plane culture carried out in the presence of an epidermal growth factor and a TGF β receptor inhibitor.

### Claim 38 (depends on 25)

A method for preparing an intestinal disease model, comprising inducing a pathological condition of an intestinal disease in the intestinal tract cell layer obtained by the preparation method according to claim 25.
